⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28877700 | 0.83 | — | — | |
| SCHEMBL6501335 | 0.73 | — | — | |
| SCHEMBL2136686 | 0.73 | — | — | |
| SCHEMBL2136680 | 0.73 | — | — | |
| SCHEMBL3250426 | 0.71 | TSHR (0.32) | — | |
| SCHEMBL8960700 | 0.70 | — | — | |
| SCHEMBL8960694 | 0.70 | — | — | |
| SCHEMBL3541800 | 0.69 | — | — | |
| SCHEMBL2118069 | 0.69 | — | — | |
| SCHEMBL2118064 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372640-B1 | USE OF THIOLUTIN DIOXIDE AND ITS DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1372640-A2 | USE OF THIOLUTIN DIOXIDE AND ITS DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS AND A PROCESS FOR THE PREPARATION THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072089-A2 | USE OF THIOLUTIN DIOXIDE AND ITS DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS AND A PROCESS FOR THE PREPARATION THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| EP-1238668-A1 | Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof | Aventis Pharma Deutschland GmbH (DE) | 2002-09-11 | — | — | EP | disclosed |